{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:17:22Z","timestamp":1782307042141,"version":"3.54.5"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In severe COVID-19, direct-acting antiviral drugs were not effective in hyperinflammatory stages and steroid treatment may weaken host immunity. The MEK inhibitor zapnometinib, as a host-targeting drug, has demonstrated promising efficacy against severe acute viral infections. Proof-of-concept for the innovative approach was presented in a clinical Phase 2 trial with hospitalized COVID-19 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The antiviral and immunomodulatory potential of zapnometinib was investigated in samples obtained from COVID-19 patients enrolled in a Phase 2 clinical trial (RESPIRE), as well as in a SARS-CoV-2 Syrian hamster model, an acute lung injury mouse model, and in cell culture. The antiviral activity of zapnometinib was assessed using viral load reduction assays and RT-qPCR. Cytokines and chemokines were analyzed via ELISA and RT-qPCR. Alterations in T and B cells from COVID-19 patients were analyzed using flow cytometry. Biomarker analysis in hamster serum was conducted to monitor potential toxic effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Zapnometinib reduced SARS-CoV-2 viral load in hospitalized COVID-19 patients, in the hamster model and in various highly pathogenic coronaviruses <jats:italic>in vitro<\/jats:italic>. Pro-inflammatory cytokines and chemokines decreased in COVID-19 patients, in a lung injury mouse model, and <jats:italic>in vitro<\/jats:italic> in primary human blood cells treated with zapnometinib. In the hamster model, zapnometinib alleviated SARS-CoV-2-mediated lung pathology. In patients with COVID-19, zapnometinib increased T and plasma B cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Unlike direct-acting antivirals, zapnometinib\u2019s dual effect highlights its therapeutic potential in the treatment of severe acute viral infections, with favorable antiviral and immunomodulatory properties.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1631721","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:21:22Z","timestamp":1758543682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Yvonne","family":"F\u00fcll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara M.","family":"Sch\u00fcssele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stenglein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"P\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Steinhilber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Anselm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Delany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M. A.","family":"Van den Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Van Amerongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"De Waal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Pleschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Planz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26010039","article-title":"COVID-19: A global challenge with old history, epidemiology and progress so far","volume":"26","author":"Khan","year":"2021","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2918-0","article-title":"Age-specific mortality and immunity patterns of SARS-CoV-2","volume":"590","author":"O\u2019Driscoll","year":"2021","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2223","DOI":"10.1002\/rmv.2223","article-title":"Sex-based differences in severity and mortality in COVID-19","volume":"31","author":"Alwani","year":"2021","journal-title":"Rev Med Virol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.761887","article-title":"Coronavirus disease 2019: clinics, treatment, and prevention","volume":"12","author":"Burkert","year":"2021","journal-title":"Front Microbiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.022","article-title":"Coronavirus (SARS-CoV-2) causes lung inflammation and injury","volume":"28","author":"Wang","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00806","article-title":"Neurological manifestations in critically ill patients with COVID-19: A retrospective study","volume":"11","author":"Fan","year":"2020","journal-title":"Front Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100617","DOI":"10.1016\/j.cpcardiol.2020.100617","article-title":"Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: A meta-analysis","volume":"45","author":"Aggarwal","year":"2020","journal-title":"Curr Probl Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.yjmcc.2020.07.003","article-title":"Coagulopathy in COVID-19: Focus on vascular thrombotic events","volume":"146","author":"Shi","year":"2020","journal-title":"J Mol Cell Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ajpath.2020.08.009","article-title":"Immunopathology of hyperinflammation in COVID-19","volume":"191","author":"Gustine","year":"2021","journal-title":"Am J Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: The role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2034982","article-title":"Baricitinib therapy in covid-19 pneumonia - an unmet need fulfilled","volume":"384","author":"Goletti","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1002\/iid3.1020","article-title":"Immunomodulatory approaches in managing lung inflammation in COVID-19: A double-edge sword","volume":"11","author":"Verma","year":"2023","journal-title":"Immun Inflammation Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050436","article-title":"Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm","volume":"9","author":"Rabaan","year":"2021","journal-title":"Vaccines"},{"key":"B19","doi-asserted-by":"publisher","first-page":"103638","DOI":"10.1016\/j.amsu.2022.103638","article-title":"Immunomodulatory effects of zinc and its impact on COVID-19 severity","volume":"77","author":"Dhawan","year":"2022","journal-title":"Ann Med Surg (Lond)."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402945","article-title":"Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141903","article-title":"Targeting tuberculosis and HIV infection-specific regulatory T cells with MEK\/ERK signaling pathway inhibitors","volume":"10","author":"Lieske","year":"2015","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2010.04.010","article-title":"The TCR-mediated signaling pathways that control the direction of helper T cell differentiation","volume":"22","author":"Nakayama","year":"2010","journal-title":"Semin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","article-title":"MEK inhibition reprograms CD8(+) T lymphocytes into memory stem cells with potent antitumor effects","volume":"22","author":"Verma","year":"2021","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1053437","article-title":"Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1039\/D3MD00145H","article-title":"MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives","volume":"14","author":"Ram","year":"2023","journal-title":"RSC Medicinal Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/35060098","article-title":"Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"104806","DOI":"10.1016\/j.antiviral.2020.104806","article-title":"Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model","volume":"178","author":"Laure","year":"2020","journal-title":"Antiviral Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.611958","article-title":"Improved in vitro efficacy of baloxavir marboxil against influenza A virus infection by combination treatment with the MEK inhibitor ATR-002","volume":"12","author":"Hamza","year":"2021","journal-title":"Front Microbiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.10.4871-4877.2001","article-title":"MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells","volume":"75","author":"Planz","year":"2001","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12955","article-title":"Late activation of the Raf\/MEK\/ERK pathway is required for translocation of the respiratory syncytial virus F protein to the plasma membrane and efficient viral replication","volume":"21","author":"Preugschas","year":"2019","journal-title":"Cell Microbiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01705-06","article-title":"Suppression of coronavirus replication by inhibition of the MEK signaling pathway","volume":"81","author":"Cai","year":"2007","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-021-05021-1","article-title":"Evaluation of kinase inhibitors as potential therapeutics for flavivirus infections","volume":"166","author":"Valencia","year":"2021","journal-title":"Arch Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.04.006","article-title":"Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Mol Ther Oncolytics."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007498","article-title":"Up-regulation of hepatitis C virus replication and production by inhibition of MEK\/ERK signaling","volume":"4","author":"Ndjomou","year":"2009","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00018-021-04085-1","article-title":"The MEK1\/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine\/chemokine responses","volume":"79","author":"Schreiber","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14091776","article-title":"The MEK1\/2 inhibitor ATR-002 (Zapnometinib) synergistically potentiates the antiviral effect of direct-acting anti-SARS-coV-2 drugs","volume":"14","author":"Schreiber","year":"2022","journal-title":"Pharmaceutics."},{"key":"B38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.antiviral.2018.07.006","article-title":"The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression","volume":"157","author":"Schrader","year":"2018","journal-title":"Antiviral Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2011.05.009","article-title":"Inhibition of influenza virus-induced NF-kappaB and Raf\/MEK\/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo","volume":"92","author":"Pinto","year":"2011","journal-title":"Antiviral Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.893635","article-title":"Pharmacokinetics, pharmacodynamics and antiviral efficacy of the MEK inhibitor zapnometinib in animal models and in humans","volume":"13","author":"Koch-Heier","year":"2022","journal-title":"Front Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1050193","article-title":"Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats","volume":"13","author":"Full","year":"2022","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102237","article-title":"Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial","volume":"102237","author":"Rohde","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9030521","article-title":"Inactivation of SARS-coV-2 through treatment with the mouth rinsing solutions viruProX((R)) and bacterX((R)) pro","volume":"9","author":"Koch-Heier","year":"2021","journal-title":"Microorganisms."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112505","article-title":"Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro","volume":"14","author":"Zekri","year":"2023","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1743-422X-2-84","article-title":"Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis","volume":"2","author":"Zielinska","year":"2005","journal-title":"Virol J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"pii=2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Euro Surveill"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1269","DOI":"10.1002\/cti2.1269","article-title":"Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2","volume":"10","author":"Watterson","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.8b00120","article-title":"Mass spectrometry-based immunoassay for the quantification of banned ruminant processed animal proteins in vegetal feeds","volume":"90","author":"Steinhilber","year":"2018","journal-title":"Anal Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.1c00478","article-title":"Matrix and sampling effects on quantification of protein biomarkers of drug-induced liver injury","volume":"20","author":"Anselm","year":"2021","journal-title":"J Proteome Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Munoz-Fontela","year":"2020","journal-title":"Nature."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314527644","article-title":"Translation strategy for the qualification of drug-induced vascular injury biomarkers","volume":"42","author":"Bendjama","year":"2014","journal-title":"Toxicol Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29802","article-title":"Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort","volume":"69","author":"Church","year":"2019","journal-title":"Hepatology."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16118","article-title":"Necrosis-released HMGB1 (High mobility group box 1) in the progressive pulmonary arterial hypertension associated with male sex","volume":"76","author":"Zemskova","year":"2020","journal-title":"Hypertension."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e0229753","DOI":"10.1371\/journal.pone.0229753","article-title":"Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments","volume":"15","author":"Schomaker","year":"2020","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41467-021-25030-7","article-title":"Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19","volume":"12","author":"Nouailles","year":"2021","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2008.145","article-title":"RNA viruses and the mitogenic Raf\/MEK\/ERK signal transduction cascade","volume":"389","author":"Pleschka","year":"2008","journal-title":"Biol Chem"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41467-021-22580-8","article-title":"Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model","volume":"12","author":"Rosenke","year":"2021","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"103403","DOI":"10.1016\/j.ebiom.2021.103403","article-title":"Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters","volume":"68","author":"Abdelnabi","year":"2021","journal-title":"Ebiomedicine."},{"key":"B61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/22221751.2021.1885998","article-title":"Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection","volume":"10","author":"Ye","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360698","article-title":"MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection","volume":"15","author":"Koch-Heier","year":"2024","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-03248-3","article-title":"Anti-COVID drug accelerates viral evolution","volume":"623","author":"Kosakovsky Pond","year":"2023","journal-title":"Nature."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41467-024-45641-0","article-title":"Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients","volume":"15","author":"Standing","year":"2024","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","first-page":"105840","DOI":"10.1016\/j.antiviral.2024.105840","article-title":"The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance","volume":"225","author":"Schreiber","year":"2024","journal-title":"Antiviral Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"104559","DOI":"10.1016\/j.ebiom.2023.104559","article-title":"Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance","volume":"91","author":"Ip","year":"2023","journal-title":"Ebiomedicine."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-coV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100044","article-title":"Randomized trial of molnupiravir or placebo in patients hospitalized with covid-19","volume":"1","author":"Arribas","year":"2022","journal-title":"NEJM Evidence."},{"key":"B70","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.lanwpc.2023.100694","article-title":"Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study","volume":"33","author":"Liu","year":"2023","journal-title":"Lancet Reg Health West Pac."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"102225","DOI":"10.1016\/j.eclinm.2023.102225","article-title":"Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study","volume":"64","author":"Wan","year":"2023","journal-title":"EClinicalMedicine."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02916-22","article-title":"Why molnupiravir fails in hospitalized patients","volume":"13","author":"Brown","year":"2022","journal-title":"mBio."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01576-3","article-title":"Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19","volume":"28","author":"Sinha","year":"2022","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31860","article-title":"Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nm1690","article-title":"Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease","volume":"13","author":"Hartl","year":"2007","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7150\/thno.15625","article-title":"Role of the CXCL8-CXCR1\/2 axis in cancer and inflammatory diseases","volume":"7","author":"Ha","year":"2017","journal-title":"Theranostics."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treata ble with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"110223","DOI":"10.1016\/j.celrep.2021.110223","article-title":"Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation","volume":"38","author":"Houde","year":"2022","journal-title":"Cell Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001198","article-title":"Adaptive immunity to SARS-CoV-2 infection: A systematic review","volume":"13","author":"Silva","year":"2022","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00721","article-title":"The maintenance of memory plasma cells","volume":"10","author":"Khodadadi","year":"2019","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194765","article-title":"Corticosteroids in acute lung injury: the dilemma continues","volume":"20","author":"Mokra","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.3.2003001","article-title":"Ventilation-induced chemokine and cytokine release is associated with activation of nuclear factor-kappaB and is blocked by steroids","volume":"163","author":"Held","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)68518-7","article-title":"The glucocorticoid dexamethasone inhibits synthesis of interferon by decreasing the level of its mRNA","volume":"263","author":"Gessani","year":"1988","journal-title":"J Biol Chem"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M709731200","article-title":"Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation","volume":"283","author":"McCoy","year":"2008","journal-title":"J Biol Chem"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-019-00628-y","article-title":"Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-kappaB\/JNK: a possible role of P-glycoprotein","volume":"28","author":"Ibrahim","year":"2020","journal-title":"Inflammopharmacology."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-023-01460-2","article-title":"The role of SARS-CoV-2-mediated NF-kappaB activation in COVID-19 patients","volume":"47","author":"Zhou","year":"2024","journal-title":"Hypertens Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2017.4033","article-title":"Repurposing of kinase inhibitors as broad-spectrum antiviral drugs","volume":"37","author":"Schor","year":"2018","journal-title":"DNA Cell Biol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00168-19","article-title":"Host-Directed Antiviral Therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"B92","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.brainres.2003.09.074","article-title":"Inhibition of MEK\/ERK 1\/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia","volume":"996","author":"Wang","year":"2004","journal-title":"Brain Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1264983","article-title":"Influenza A virus replication has a stronger dependency on Raf\/MEK\/ERK signaling pathway activity than SARS-CoV-2","volume":"13","author":"Hoffmann","year":"2023","journal-title":"Front Cell Infection Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1631721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:21:22Z","timestamp":1758543682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1631721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":93,"alternative-id":["10.3389\/fimmu.2025.1631721"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1631721","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1631721"}}